Competent authorities, healthcare payers and hospitals devote increasing resources for quality management systems but scientific analyses searching for an impact on clinical outcome remain scarce. Earlier data indicated a stepwise improvement in outcome after allogeneic hematopoietic stem cell transplantation with each phase of the accreditation process for the quality management system "JACIE". We therefore tested the hypothesis that working towards and achieving "JACIE" accreditation would accelerate improvement in outcome over 
Introduction
Implementation of a quality management system (QMS) has become standard practice for industries when their products or services are associated with significant risks to human safety. Use of a QMS contributes to better products and services. It raises consumers' trust and confidence; it is associated with stronger customer loyalty, more repeat sales, less vulnerability to price pressures and lower marketing expenditures 1,2 . As a consequence, "Quality Management" has become an essential component of today's management strategies [3] [4] [5] [6] [7] .
Use of quality management systems and accreditation has been advocated as a putative driver for quality, safety and reduced costs in Health Care as well. First introduced about two decades ago in hospital pharmacies and laboratories 8 , quality management has altered previously established mechanisms, induced structural changes and promoted high quality organizational processes. It has improved structures of Health Services organizations and altered professionals' attitudes towards external and internal assessment [9] [10] [11] [12] [13] . Competent authorities, healthcare payers and hospitals devote increasing resources for quality management systems and for accreditation or certification of parts or all of their activities.
Still, evidence for improved patient outcome is scarce [14] [15] [16] [17] . With increasing financial constraints, questions about the value of the large sums invested in health services accreditation arose in recent years [17] [18] [19] [20] .
Hematopoietic stem cell transplantation (HSCT) is an established treatment for many patients with severe congenital or acquired disorders of the hematopoietic system. Despite major improvements, it remains associated with substantial morbidity and mortality [21] [22] [23] [24] .
HSCT requires the cooperation of many categories of healthcare professionals. Hence, it presents a role model to assess the value of a QMS which defines infrastructures, equipment, release of the products or services, responsibilities, training of personnel, acceptable criteria for admission and discharge, and requires implementation of standard operating procedures and continuous improvement strategies as key elements [3] [4] [5] [6] [7] .
In this context, "JACIE" (www.jacie.org) and its US equivalent counterpart "FACT"
(www.factwebsite.org) have developed an evolving set of identical standards (kindly provided initially by FACT and currently in its 5 th version) that require an ongoing QMS and apply to clinical, collection and processing activities. Centers seeking accreditation are subject to a detailed document review, on-site inspection and auditing procedure as is used in any industrial total quality management program 25, 26 . A preliminary analysis, based on a small number of patients transplanted in an accredited center showed a significant stepwise reduction of early mortality by each phase of the accreditation process for patients transplanted in accredited centers 27 . We therefore tested the hypothesis that improvement in outcome would begin long before final "JACIE" accreditation, extend during post transplant follow up and hence lead to a more rapid reduction of mortality over calendar years.
Methods

Study design
This retrospective observational analysis was based on the previously published cohort of the EBMT database; it begins at January 1 st 1999, three years before the first center in accreditation at any time thereafter. All EBMT teams are required to obtain patient's consent and to have internal review board approval for evaluation of their transplant programs and for data transfer to EBMT.
Patient population
The cohort included 107,904 patients, 59% males, with a first allogeneic (N= 41,623; 39%) or autologous (N= 66,281; 61%) HSCT for an acquired hematological disease (Table 1) . There were significant changes in the patient population from 1999 to 2006 with an increasing proportion of acute and a relative decrease in chronic leukemia as main diagnosis and a steady increase in EBMT risk score [27] [28] [29] .
Statistical analysis
Focus of the statistical approach was on the interaction between "JACIE" accreditation and calendar time on mortality reduction with adjustments for the key known risk factors. ), patient age, donor type, conditioning, calendar year, centre, centre size analyzed as successive quartiles, and Gross National Income per capita (GNI/cap) of the center's country 24 (data obtained from www.worldbank.org) were used as main confounders, cluster or stratification variables.
An extended COX proportional hazards model was chosen. Cause specific hazards were calculated, taking relapse and death as competing risks. Disease and conditioning were considered as stratification factors, since survival of patients with different diseases was not proportional (Figure 1 ) and conditioning was not a target of the analysis. The effect of accreditation was estimated by using a different baseline within each strata and averaged over the categories. All covariates were truly patient-level covariates, except for "JACIE pos " accreditation, "GNI/cap" and "center size" which was shared among all patients transplanted at the same time and place. This "JACIE" variable as defined above served as a covariate to predict outcome at the patient level, not at the center level.
Endpoints in all analyses were overall survival, relapse free survival, relapse incidence and non-relapse mortality 28 . The interaction terms tested were "JACIE"*size, "JACIE*calendar year, "JACIE"*age, and "JACIE*GNI/cap. For comparability reasons we evaluated the same models with and without the remaining significant interaction terms to get a separate as well as a pooled (adjusted) "JACIE" effect.
Results
There were differences between the groups. Centers with JACIE accreditation by 2012
were more likely to have higher total transplant numbers, to be in countries with a higher GNI/cap, to perform more allogeneic HSCT, to do so with a higher proportion of alternative donors, to have more patients with a higher EBMT risk score, and to have fewer missing values. 28 . The probability of overall survival at 6 years was 47% for recipients of an allogeneic HSCT (non relapse mortality 29%, relapse incidence 30%, relapse free survival 40%) and 57% for patients with an autologous HSCT (non relapse mortality 11%, relapse incidence 49%, relapse free survival 40%) with wide variations depending on main disease (Fig 1a, 1b) .
Main risk factors and outcome after HSCT
Data showed a systematic decrease in overall and relapse free survival related to a systematic increase in non relapse mortality and relapse incidence with increasing EBMT risk score for both allogeneic (Fig 1c) and autologous (Fig 1d) The annual improvement over the 14-year observation period was significantly faster in accredited centers. The overall mortality rate was decreasing by a factor of 0. Of note, median follow-up of survivors was significantly longer among accredited centers (72 vs 61 months) and significantly longer for patients with an allogeneic compared to an autologous HSCT. This difference may both denote the association between accreditation and improved follow-up, and lead to an underestimation of benefits associated with accreditation.
Discussion
These data provide a clear view on the potential impact of accreditation in medical practice in general and specifically in HSCT. Results became better in all centers over calendar time but they improved significantly faster and were more pronounced for patients transplanted in accredited programs. As a consequence, non relapse mortality and relapse incidence were lower, and relapse free survival and overall survival were significantly better for patients having received their allogeneic HSCT in centers accredited for the QMS "JACIE" by the year 2012. This difference in outcome was observed as early as at day 100 and continued up to 72 months after HSCT. The effects were substantial, systematic and clinically relevant with an overall improvement of 10-15%. The data suggest that accreditation as an indicator for quality driven work was the single most important contributing factor to the substantial improvement over time. More importantly, introduction of a QMS can induce visible changes in a medical team long before final accreditation. This fits with observations from QMS work in industrial production [3] [4] [5] [6] [7] .
No such effects could be demonstrated for patients with an autologous HSCT.
The analysis revealed additional new findings. Outcome was, in addition to the known risk factors such as EBMT risk score, age or donor type, significantly and systematically influenced by center size, GNI/capita and calendar year, in addition to the known risk factors such as EBMT risk score, age or donor type. The improvement occurred stepwise, results improved independent of the accreditation over calendar years. Outcome was better, the larger the centers, and the richer their respective country. The patient populations changed over time and differed between accredited and non-accredited programs as well as between small and large centers making the analysis more complex. The only statistically significant interaction found, however, was between the accreditation process and the year of transplant in allogeneic HSCT. All other tested interactions, including center size, EBMT risk score, age or GNI/cap were insignificant. Hence, our observations, based on clustered survival models of individual patients with identical characteristics, through stratification by disease and conditioning regimen, clustering by center, and modeling calendar year, risk score, age, donor relation and GNI/cap as covariates did respect the full diversity of the patient populations and the teams. The analysis showed that accreditation was associated with improved outcome for all patients undergoing allogeneic HSCT, pediatric or adult patients, in all diseases, in small and large centers and in countries with low or high GNI/cap.
Not all factors known to influence outcome after HSCT were included in the analysis such as co morbidity score, viral status or cytokine polymorphisms; no adjustment for modern HLAtyping of unrelated donors was made. Similarly, the accreditation process did not assess all potential factors influencing team performance 30 .There was, however, no hint of any additional interaction that could explain the JACIE accreditation status as a simple surrogate marker for an unknown unrelated effect. It is therefore likely, by all limitations of an observational study, that the findings are indeed sufficiently unbiased and robust; these results cannot be reduced to a simple centre effect, learning curve, cumulative experience or case load [31] [32] [33] [34] [35] . It remains possible that accredited centers were more prone to quality work and that accreditation remains as a surrogate marker for quality consciousness. Still, data showed a close relationship between the individual steps of the accreditation process and the improvements; they showed a clear difference in speed of improvement over calendar time between accredited and non-accredited centers. These observations over a long time span support evidence for a more causal than casual relationship.
The absence of a "JACIE effect" after autologous HSCT warrants an explanation. Focus of the analysis was on survival, the strongest and unambiguous endpoint; potential effects on quality of life, hospitalization time or costs were not evaluated. A QMS includes multiple elements. It includes description of responsibilities, continuous quality improvement strategies and error management; it mandates standard operating procedures for patient (and donor) selection, transplant techniques, the stem cell product and follow-up; it stipulates data collection and data analysis as integral parts of the therapy. Any QMS is therefore more likely to manifest its benefit after the clinically more complex procedure of an allogeneic HSCT with its longer lasting link of patients to the transplant team.
Our observations support integration of a QMS into complex medical therapeutic strategies, including solid organ transplantation 37, 38 . The focus in regulatory aspects should no longer be on centre size alone (minimal numbers of procedures being themselves requirements for "JACIE" accreditation) or on the sole use of center specific outcome data.
Last, the clear differences between autologous and allogeneic HSCT suggest next steps to do.
Probably, quality management should no longer be restricted to just one phase of the treatment, the immediate transplant period, but cover the whole treatment program, from 
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Methods in Details
Study design
This was a retrospective observational analysis, based on a well-defined previously published cohort of the EBMT database 27 . The cohort begins with the first calendar year, January 1 st 1999, in which at least one centre started to work towards accreditation and ends More importantly, we were in a position to test our hypothesis that working towards and achieving accreditation for the quality management system "JACIE" would accelerate improvement in outcome over calendar time and, to quantify the potential impact on outcome.
We postulated that the organizational and cultural changes associated with the introduction of a quality management system 3,9,14 should already be detectable The analysis was censored at 72 months to achieve optimal comparability between all patients regardless of calendar year. The median survival among censored patients of the initial cohort was 70 months (6 months for patients who died). All EBMT teams are required to obtain patient's consent and to have internal review board approval for evaluation of their transplant programs and for data transfer to EBMT.
Patient population
The cohort included 107,904 patients, with a first allogeneic (N= 41,623; 39%) or autologous (N= 66,281; 61%) hematopoietic stem cell transplantation for an acquired hematological disease (Table 1) . The main diagnostic categories were: acute leukemia (29484; 27%; 78% allogeneic), chronic leukemia (9652; 9%; 84% allogeneic), lymphoma (36512; 34%; 9% allogeneic), plasma cell disorders (25840; 24%; 4% allogeneic), myelodysplastic syndromes and myeloproliferative neoplasms (4199; 4%; 94% allogeneic), or bone marrow failure syndromes (2217;2%; 100% allogeneic). Median age at transplant was 48 years (range 1 -85 years); there were more male than female patients (59 %). with JACIE accreditation by 2012 were more likely to perform allogeneic hematopoietic stem cell transplantation, to do so with a higher proportion of alternative donors, to have more patients with a higher EBMT risk score, and to have higher total transplant numbers.
Statistical analysis
Focus of the statistical approach was on the interaction between "JACIE + " and calendar time on mortality reduction with adjustments for the key known risk factors. A completely different analysis framework has been chosen to test the hypothesis and to verify consistency between the two approaches. Based on the earlier analysis, the statistical models were kept as generic as possible and did concentrate on the accreditation status categories 27 .
Main disease, EBMT risk score, patient age, donor type, conditioning, calendar year, centre, centre size, and Gross National Income per capita of the center's country 24 (data obtained from www.worldbank.org) were used as main confounders, cluster or stratification variables.
Although patient age is contained in the EBMT risk score, the effect of age is not captured sufficiently by that score. Hence age itself was added to all models as a factor ("below 20","20-40","40-60" and "over 60") thus increasing significantly the goodness-of-fit of all models and therefore removing age related bias not covered by the EBMT risk score.
An extended COX proportional hazards model was chosen. Cause specific hazards were calculated, taking relapse and death as competing risks. Disease (main disease categories) and conditioning (reduced intensity versus standard) were considered as stratification factors, since survival of patients with different diseases was not proportional (Figure 1 ) and conditioning was not a target of the analysis. Therefore, the effect of "JACIE" was estimated by using a different baseline within each disease and conditioning, and averaged over the disease categories. All covariates were truly patient-level covariates, except for "JACIE", Gross National Income/capita and "Size". "JACIE" was shared among all patients transplanted in one particular centre and in one particular calendar year. This "JACIE" variable as defined above served as a covariate to predict outcome at the patient level, not at the center level. Hence, all patients transplanted in one particular center in one particular calendar year shared the same value of this risk factor. "Gross National Income/capita" was shared among all patients transplanted in one particular country and in one particular calendar year. "Size" was shared among all patients transplanted in one particular center, in one particular calendar year and with one particular conditioning regimen.
The COX models fitted to the data were clustered models, taking into account the center identification as cluster variable to ensure that the within-center correlation was taken into account. The models were not truly random effect models. "JACIE" accreditation was taken as a fixed factor, just as center size and Gross National Income/capita; these effects were estimated by its size, taking a within-center clustering and interactions into account.
"JACIE" and centre size (in quartiles, calculated for each team for each calendar year, and separate for allogeneic and autologous hematopoietic stem cell transplants) and Gross National Income/capita (calculated in quartiles for each country) were the only covariates operating at the center level. All other covariates were considered as patient and treatment characteristics. Calendar year was introduced in all models as a continuous factor and expressed as Hazard Ratios per 10 years.
The effects of EBMT risk score, age, center size, donor relation and Gross National Income/capita were assessed by introducing them as a factor in the model, leaving the other risk factors as stratification factors, thus adjusting fully and with model assumptions for their various effects. Endpoints in all analyses were overall survival, relapse free survival, relapse incidence and non-relapse mortality 28 . The interaction terms introduced and tested for significance were "JACIE"*size, "JACIE"*calendar year, "JACIE"*age and "JACIE"* Gross National Income/capita (of which only "JACIE"*calendar year remained after removal of non-significant interactions). For comparability reasons we evaluated the same models with and without the remaining significant interaction terms to get a separate (by year) as well as a pooled (adjusted) "JACIE" effect.
